Reuters
03 Sept 2026, 10:32 UTC · 8w ago
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
Impact · against what's priced in
Ultragenyx faces a significant valuation write-down following the late-stage trial failure of its Angelman syndrome treatment. The collapse of a primary growth driver justifies the sharp price decline as the market removes expected future revenues from the company's valuation.
- RARE−0.90
No priced-in read yet
- In context
The failure of a closely watched late-stage trial for a neurodevelopmental disorder treatment removes one of the company's biggest growth bets, leading to a premarket plunge of over 40%.
Read from the article alone
Search tags
